Q Genetics secured investment from K-Ground Partners' IP Fund, giving impetus to its new drug development endeavors. Subsequent to the completion of its Phase 1 trial, t ...

Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ETCompany ParticipantsKurt Gustafson - Chief Financial OfficerMatt ...

In one advertisement, Fife flagged in 2023, a skin substitute representative whose company name has been redacted boasts of a ...

In vitro tests indicate that cannabidiol can stimulate the biomineralization of teeth even under inflammatory conditions, ...

Federal funding for psychological research is in chaos. Here's one lab's story of the impacts of this funding confusion and ...

AstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases.

Neurodegenerative diseases represent a significant challenge in medical science, impacting millions globally. Despite advancements in diagnostic technology, ...

The Clinical Trials Research Pillar in the Division of Biostatistics is at the forefront of innovative clinical trial design ...

Shearwater Health, a leader in clinician-led clinical solutions for healthcare partners, is pleased to announce that it has been named one of the nation’s top Utilization Management (UM) service ...

Learn how drug absorption and predictive modeling drive advancements in pharmaceuticals and precision medicine.

Explore the barriers Black women face in clinical trials and learn how to increase participation, trust, and diversity in medical research.

Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. ("CytoDyn" or the "Company"). On February 24, 2025 ...